Literature DB >> 8761480

The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).

J C O'Connell1, J F McCallum, I McPhee, J Wakefield, E S Houslay, W Wishart, G Bolger, M Frame, M D Houslay.   

Abstract

The PDE4A (type IV) cAMP-specific, rolipram-inhibited phosphodiesterase RPDE-6 (RNPDE4A5), when transiently expressed in COS7 cells, could be complexed with the v-Src-SH3 domain expressed as a glutathione S-transferase (GST) fusion protein. RPDE-6 did not interact with GST itself. This complex was not disrupted by treatment with high NaCl concentration together with Triton X-100. Interaction was apparently determined by the N-terminal splice region of RPDE-6, as the PDE4A splice variant RPDE-39, which differs from RPDE-6 at the extreme N-terminus, failed to associate with v-Src-SH3; met26RD1 (where RD1 is rat 'dunc-like' PDE), which has the N-terminal splice region deleted, failed to associate with v-Src-SH3, and the association of RPDE-6 and v-Src-SH3 was blocked by a fusion protein formed from the N-terminal splice region. RDPE-6 showed binding to GST fusion proteins of both the intact Src kinase and an SH2-SH3 construct but did not bind to the Src-SH2 domain or to the adaptor protein Grb-2. RPDE-6 could be co-immunoprecipitated from cytosol extracts of transfected cells by using anti-Src antiserum. RPDE-6 exhibited selectivity in binding to the SH3 domains of c-Abl, Crk, Csk, Lck, Lyn, Fyn and v-Src, with binding to the SH3 regions of the Src-related tyrosyl kinases Lyn and Fyn being the most effective. The binding of RPDE-6 to the SH3 domains of Crk, Csk and Lck led to a marked reduction in PDE activity, but no change was apparent in complexes with other species. Endogenous RPDE-6 from brain, but not endogenous RPDE-39 from testis, bound to the Src-SH3 domain. We suggest that the PDE4A splice variant RPDE-6 has a propensity for interaction with selective SH3 domains, in particular those from Src and the Src-related tyrosyl kinases Lyn and Fyn. This interaction seems to be governed by alternative splicing of the PDE4A gene, because RPDE-39, a splice variant that lacks the proline-rich N-terminal splice region of RPDE-6, does not interact with these SH3 domains. It is proposed that the binding site on RPDE-6 for SH3 domains lies within the unique first 102 residues of its N-terminal splice domain, where two motifs representing Class I SH3 binding sites with selectivity for Src kinase SH3 domains can be identified and one motif for a putative Class II SH3 binding site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761480      PMCID: PMC1217616          DOI: 10.1042/bj3180255

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  40 in total

1.  Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase.

Authors:  G W Booker; I Gout; A K Downing; P C Driscoll; J Boyd; M D Waterfield; I D Campbell
Journal:  Cell       Date:  1993-05-21       Impact factor: 41.582

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected].

Authors:  Y M Horton; M Sullivan; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

4.  Vav binds to several SH2/SH3 containing proteins in activated lymphocytes.

Authors:  F Ramos-Morales; B J Druker; S Fischer
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

5.  Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites.

Authors:  L Monaco; E Vicini; M Conti
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

6.  Multiple cyclic nucleotide phosphodiesterases.

Authors:  J A Beavo; M Conti; R J Heaslip
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

7.  Recombinant Csk expressed in Escherichia coli is autophosphorylated on tyrosine residue(s).

Authors:  C Bougeret; B Rothhut; P Jullien; S Fischer; R Benarous
Journal:  Oncogene       Date:  1993-05       Impact factor: 9.867

8.  The crystal structure of the N-terminal SH3 domain of Grb2.

Authors:  L Guruprasad; V Dhanaraj; D Timm; T L Blundell; I Gout; M D Waterfield
Journal:  J Mol Biol       Date:  1995-05-12       Impact factor: 5.469

9.  The crystal structure of human CskSH3: structural diversity near the RT-Src and n-Src loop.

Authors:  T V Borchert; M Mathieu; J P Zeelen; S A Courtneidge; R K Wierenga
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

10.  Independent binding of peptide ligands to the SH2 and SH3 domains of Grb2.

Authors:  M A Lemmon; J E Ladbury; V Mandiyan; M Zhou; J Schlessinger
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

View more
  12 in total

1.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

2.  Interaction of two proline-rich sequences of cell adhesion kinase beta with SH3 domains of p130Cas-related proteins and a GTPase-activating protein, Graf.

Authors:  T Ohba; M Ishino; H Aoto; T Sasaki
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

3.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

4.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.

Authors:  S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

Review 5.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

Review 6.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Intracellular membrane association of the Aplysia cAMP phosphodiesterase long and short forms via different targeting mechanisms.

Authors:  Kun-Hyung Kim; Yong-Woo Jun; Yongsoo Park; Jin-A Lee; Byung-Chang Suh; Chae-Seok Lim; Yong-Seok Lee; Bong-Kiun Kaang; Deok-Jin Jang
Journal:  J Biol Chem       Date:  2014-07-30       Impact factor: 5.157

8.  Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2.

Authors:  M Sullivan; G Rena; F Begg; L Gordon; A S Olsen; M D Houslay
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

9.  Involvement of Src family of kinases and cAMP phosphodiesterase in the luteinizing hormone/chorionic gonadotropin receptor-mediated signaling in the corpus luteum of monkey.

Authors:  Shah B Kunal; Asaithambi Killivalavan; Rudraiah Medhamurthy
Journal:  Reprod Biol Endocrinol       Date:  2012-03-29       Impact factor: 5.211

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.